Use of self-delivery siRNAs to inhibit gene expression in an organotypic pachyonychia congenita model

Journal of Investigative Dermatology

Volumn 131, Issue 5, 2011, Pages 1037-1044

  Hickerson, Robyn P ^a   Flores, Manuel A ^a   Leake, Devin ^b   Lara, Maria F ^c   Contag, Christopher H ^c   Leachman, Sancy A ^d   Kaspar, Roger L ^a,c  

^a TransDerm Inc   (United States)

^b Thermo Fisher Scientific   (United States)

^c STANFORD UNIVERSITY   (United States)

^d UNIVERSITY OF UTAH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ENHANCED GREEN FLUORESCENT PROTEIN; KERATIN; LENTIVIRUS VECTOR; MESSENGER RNA; SMALL INTERFERING RNA;

ARTICLE; BIOLUMINESCENCE; CHEMICAL MODIFICATION; COMPETITIVE INHIBITION; CONGENITAL PACHYONYCHIA; CONTROLLED STUDY; DRUG EFFICACY; DRUG UPTAKE; EPIDERMIS; GENE EXPRESSION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LENTIVIRINAE; PRIORITY JOURNAL; REPORTER GENE; RNA INTERFERENCE; RNA SEQUENCE; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WILD TYPE;

EID: 79954976090     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.426     Document Type: Article

References (30)

1. Berkowitz RD, Ilves H, Plavec I et al. (2001) Gene transfer systems derived from Visna virus: analysis of virus production and infectivity. Virology 279:116-29 (Pubitemid 34162554)
2. Dull T, Zufferey R, Kelly M et al. (1998) A third-generation lentivirus vector with a conditional packaging system. J Virol 72:8463-71 (Pubitemid 28471781)
3. Follenzi A, Ailles LE, Bakovic S et al. (2000) Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25:217-22 (Pubitemid 30394997)
4. Geusens B, Sanders N, Prow T et al. (2009) Cutaneous short-interfering RNA therapy. Expert Opin Drug Deliv 6:1333-49
5. Gonzalez-Gonzalez E, Ra H, Hickerson RP et al. (2009) siRNA silencing of keratinocyte-specific GFP expression in a transgenic mouse skin model. Gene Therapy 16:963-72
6. Gonzalez-Gonzalez E, Ra H, Spitler R et al. (2010a) Increased interstitial pressure improves nucleic acid delivery to skin enabling a comparative analysis of constitutive promoters. Gene Therapy 17:1270-8
7. Gonzalez-Gonzalez E, Speaker TJ, Hickerson RP et al. (2010b) Silencing of reporter gene expression in skin using siRNAs and expression of plasmid DNA delivered by a soluble protrusion array device (PAD). Mol Therapy 18:1667-74
8. Heller LC, Heller R (2006) In vivo electroporation for gene therapy. Hum Gene Ther 17:890-7 (Pubitemid 46076749)
9. Hickerson RP, Smith FJ, Reeves RE et al. (2008) Single-nucleotide- specific siRNA targeting in a dominant-negative skin model. J Invest Dermatol 128:594-605 (Pubitemid 351252662)
10. Hickerson RP, Leachman SA, Pho LN et al. (2010) Development of quantitative molecular clinical endpoints for siRNA clinical trials. J Invest Dermatol; e-pub ahead of print 30 December 2010
11. Kaspar R, McLean W, Schwartz M (2009) Achieving successful delivery of nucleic acids to skin: 6th Annual Meeting of the International pachyonychia congenita Consortium. J Invest Dermatol 129:2085-7
12. Kigasawa K, Kajimoto K, Hama S et al. (2010) Noninvasive delivery of siRNA into the epidermis by iontophoresis using an atopic dermatitis-like model rat. Int J Pharm 383:157-60
13. Leachman SA, Hickerson RP, Hull PR et al. (2008) Therapeutic siRNAs for dominant genetic skin disorders including pachyonychia congenita. J Dermatol Sci 51:151-7
14. Leachman SA, Hickerson RP, Schwartz ME et al. (2010) First-in-human mutation-targeted siRNA phase Ib trial of an inherited skin disorder. Mol Therapy 18:442-6
15. Leachman SA, Kaspar RL, Fleckman P et al. (2005) Clinical and pathological features of pachyonychia congenita. J Investig Dermatol Symp Proc 10:3-17
16. Liu H, Patel MR, Prescher JA et al. (2010) Cancer stem cells from human breast tumors are involved in spontaneous metastases in orthotopic mouse models. Proc Natl Acad Sci USA 107:18115-20
17. Lorenz C, Hadwiger P, John M et al. (2004) Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 14:4975-7 (Pubitemid 39165605)
18. Meade BR, Dowdy SF (2009) The road to therapeutic RNA interference (RNAi): Tackling the 800 pound siRNA delivery gorilla. Discov Med 8:253-6
19. Michiue H, Eguchi A, Scadeng M et al. (2009) Induction of in vivo synthetic lethal RNAi responsestotreatglioblastoma. Cancer Biol Ther 8:2306-13
20. Schwarz DS, Ding H, Kennington L et al. (2006) Designing siRNA that distinguish between genes that differ by a single nucleotide. PLoS Genet 2:e140
21. Smith FJ, Hickerson RP, Sayers JM et al. (2008) Development of therapeutic siRNAs for pachyonychia congenita. J Invest Dermatol 128:50-8 (Pubitemid 350249391)
22. Smith FJD, Kaspar RL, Schwartz ME et al. (2006) Pachyonychia congenita. Gene Rev:www.genetests.org/profiles/pc
23. Soutschek J, Akinc A, Bramlage B et al. (2004) Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173-8 (Pubitemid 39545841)
24. Takei Y, Nemoto T, Mu P et al. (2008) In vivo silencing of a molecular target by short interfering RNA electroporation: tumor vascularization correlates to delivery efficiency. Mol Cancer Ther 7:211-21
25. Vaishnaw AK, Gollob J, Gamba-Vitalo C et al. (2010) A status report on RNAi therapeutics. Silence 1:14
26. Wang Q, Ilves H, Chu P et al. (2007) Delivery and inhibition of reporter genes by small interfering RNAs in a mouse skin model. J Invest Dermatol 127:2577-84 (Pubitemid 47585057)
27. Wilson NJ, Leachman SA, Hansen CD (2011) A large mutational study in pachyonychia congenita. J Invest Dermatol 131:1018-24
28. Whitehead KA, Langer R, Anderson DG (2009) Knocking down barriers: advances in siRNA delivery. Nat Rev Drug Discov 8:129-38
29. Wu Y, Navarro F, Lal A et al. (2009) Durable protection from Herpes Simplex Virus-2 transmission following intravaginal application of siRNAs targeting both a viral and host gene. Cell Host Microbe 5:84-94
30. Yi M, Wu P, Trevorrow KW et al. (1999) Evidence that the Igkappa gene MAR regulates the probability of premature V-J joining and somatic hypermutation. J Immunol 162:6029-39 (Pubitemid 29314961)